Partnership Aims to Develop ‘Liquid’ Biopsies for Prostate and Bladder Cancers That Rely on Blood

Partnership Aims to Develop ‘Liquid’ Biopsies for Prostate and Bladder Cancers That Rely on Blood
Biocept and Dr. Shilpa Gupta, an expert in cancers of the genitourinary tract, are working together to develop liquid, or blood-based, biopsies for patients with bladder and prostate cancer that may help improve the diagnosis and treatment of those cancers. Dr. Gupta, an assistant professor in the Division of Hematology, Oncology and Transplantation at Masonic Cancer Center, University of Minnesota, has served as the principal investigator in a number of clinical trials into bladder and prostate cancer.  "We are delighted to be working with Dr. Gupta, a leading expert in the field of genitourinary cancers, including bladder and prostate cancers and the role of targeted therapies and immunotherapy agents in these disease states," Veena Singh, MD, Biocept's senior vice president and senior medical director, said in a press release. "Dr. Gupta has been an active speaker at national and international forums discussing the role of novel therapeutics for personalized medicine in prostate cancer." The proposed study will assess the utility of Biocept's patented Target Selector liquid biopsy technology platform in detecting the expression of PD-L1 and androgen receptor (AR) in circulating tumor cells (CTCs). CTCs are cells that detach from the primary tumor and enter the bloodstream. In some cases, these cells can be tested to understand a tumor's general behavior, including changes in gene expression and tumor-acquired mutations that can be involved
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *